Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

NCT00839111 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: sorafenib
DRUG: FOLFIRI

Sponsor

Fudan University